Free Pulmonology CME

  • FREE

    Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies

    Interstitial lung disease (ILD) is a collective term used to categorize more than 200 different types of diseases that affect the alveolar structures, the pulmonary interstitium, and small airways.

    After completing Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies you will be able to:

    • Describe the pathophysiology of and risk factors for ILD-PF such that it might inform treatment mechanisms and strategies
    • Identify signs and symptoms of ILD-PF (e.g., rheumatoid arthritis, chronic hypersensitivity pneumonitis, unclassified ILD)
    • Describe the prevalence, morbidity, and mortality, burden of illness associated with ILD-PF and, conversely, the benefits associated with early identification and treatment
    • Describe current treatment standards and monitoring parameters (HRCT, PFTs) of ILD-PF, including developments in clinical research and treatment guidelines, and apply them to patient cases
    • Discuss ways to improve clinician communication with their patients, including disease education

     

    Target Audience: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with ILD-Pf.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: January 27, 2019
    • Expiration of CME credit: January 27, 2021
  • FREE

    Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care

    Topics covered in Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care include:
    Epidemiology, clinical features, presentation, pathophysiology, and disease progression, patient population identification among healthcare professionals of different specialties, diagnostic tests, genetic testing and patient cases.

    After completing Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care, you will be able to:
    • Describe the pathophysiology of AATD and how it impacts treatment of the disorder
    • Assess the clinical significance of AATD laboratory results and apply them to patient cases
    • Describe the clinical presentation of patients with A1ATD and, given a patient case, formulate a treatment plan
    • Recall barriers to care for AATD and its clinical management in current practice

    Target Audiences:
    Pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: June 26, 2017
    • Expiration of CME credit: June 26, 2019
  • FREE

    Pilot for Pulmonary COPD Expert Interviews

    Pilot for Pilot for Pulmonary COPD Expert Interviews reviews topics including:
    • What is the 2017 GOLD standard for managing patients with COPD?
    • Stepping up or stepping down – which direction for COPD patients?
    • Is the delivery system a good match for your patients with COPD?

    After completing the Pilot for Pilot for Pulmonary COPD Expert Interviews, you should be better able to:
    • Examine the data and expert recommendations concerning the use of ICS in patients with COPD
    • Evaluate data on the use of single and combination bronchodilators in patents with COPD
    • Discuss clinical scenarios where ICS should or should not be considered

    Target Audiences:
    Pulmonologists, critical care clinicians and other healthcare professionals involved in the management of patients with COPD.

    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: The France Foundation
    • Format: On-Demand Online
    • Material last updated: May 31, 2017
    • Expiration of CME credit: May 31, 2018
  • FREE

    Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): Optimizing Treatment Strategies

    Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): Optimizing Treatment Strategies is a free CME course that looks into the diangosis and treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD).

    Topics covered in this course include

    • SSc-ILD Epidemiology and risk factors
    • SSc-ILD Pathophysiology
    • SSc-ILD Diagnosis
    • Treatment of SSc-ILD
    • SSc-ILD

    After completing this course, you will better be able to:

    • Describe the etiology of SSc-ILD and its impact on patient clinical presentation and available pharmacotherapeutic treatments
    • Describe the prevalence, clinical features, and presentation of SSc-ILD
    • Evaluate treatments plans for SSc-ILD patients and suggest appropriate therapies, where applicable, based on individual presentations
    • Describe present and emerging drug therapies for management of SSc-ILD and apply them to patient cases taking into account the patient’s history
    • Describe clinical and logistical challenges associated with treating and educating patients with SSc-ILD

    Target audience: The following HCPs: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with Ssc-ILD.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: August 20, 2018
    • Expiration of CME credit: July 20, 2020